Table 1.
Baseline demographics of the enrolled HCC patients
| Variable | BCLC A (n = 1,210) | SLHCC (n = 466) | BCLC B (n = 609) | p |
|---|---|---|---|---|
| Patient demographics | ||||
| Age, years | 67 (57–75) | 69 (57–79) | 67 (58–76) | 0.200 |
| Male sex | 882 (72.9%) | 375 (80.5%) | 460 (75.5%) | 0.005 |
| Serum biochemistry tests and liver function tests | ||||
| Albumin, g/dL | 3.90 (3.40–4.20) | 3.80 (3.40–4.10) | 3.60 (3.10–4.00) | 0.787 |
| Total bilirubin, mg/dL | 0.77 (0.53–1.16) | 0.73 (0.53–1.12) | 0.80 (0.55–1.21) | 0.554 |
| Alanine aminotransferase, U/L1 | 39 (26–63) | 42 (26–63) | 47 (30–77) | 0.074 |
| Aspartate aminotransferase, U/L1 | 41 (28–68) | 47 (32–86) | 57 (38–94) | <0.001 |
| Creatinine, mg/dL1 | 0.92 (0.78–1.13) | 0.94 (0.77–1.14) | 0.94 (0.78–1.18) | 0.421 |
| Alkaline phosphatase, U/L1 | 80 (63–106) | 96 (73–131.75) | 108 (79–155) | <0.001 |
| Platelets, /mm3 | 131,000(86,000–177,000) | 187,000(136,000–240,000) | 143,000(101,000–210,000) | <0.001 |
| PT/INR1 | 1.07 (1.01–1.14) | 1.06 (1.01–1.11) | 1.08 (1.03–1.17) | 0.631 |
| Viral factors | ||||
| HBsAg (+/–)1 | 599/452 (57.0/43.0%) | 228/203 (52.9/47.1%) | 284/272 (51.1/48.9%) | 0.058 |
| Anti-hepatitis C virus (+/–)1 | 380/605 (38.6/61.4%) | 84/336 (20/80%) | 188/364 (34.1/64.5%) | <0.001 |
| Antiviral therapy (yes/no) | 359/851 (29.7/70.3%) | 54/412 (11.6/88.4%) | 91/518 (14.9/85.1%) | <0.001 |
| Tumor factors | ||||
| Tumor size, cm | 2.8 (2.3–3.5) | 8.0 (6.5–11.13) | 5.10 (3.50–8.20) | <0.001 |
| Tumor number (single/multiple) | 942/268 (77.9/22.1%) | 466/0 (100/0%) | 0/609 (0/100%) | <0.001 |
| Alpha-fetoprotein, ng/mL1 | 16.71 (5.53–89.11) | 39.14 (5.23–1438.74) | 62.50 (9.48–928.52) | <0.001 |
| EVs (+/–)1 | 215/908 (19.1/80.7%) | 43/376 (10.3/89.7%) | 96/429 (18.3/81.7%) | <0.001 |
| ALBI grade (1/2/3) | 539/583/88(44.5/48.2/7.3%) | 197/236/33(42.3/50.6/7.1%) | 197/324/88(32.3/53.2/14.5%) | <0.001 |
| Curative/noncurative treatment | 939/271 (77.6/22.4%) | 251/215 (53.9/46.1%) | 167/442 (27.4/72.6%) | <0.001 |
Continuous variables are expressed as median with 25th and 75th percentiles. ALBI, albumin-bilirubin; BCLC, Barcelona Clinic Liver Cancer; EVs, esophageal varices; HBsAg, hepatitis B virus surface antigen; HCC, hepatocellular carcinoma; PT/INR, prothrombin time/international normalized ratio; SLHCC, single large hepatocellular carcinoma.
1
Missing data at the time of HCC diagnosis in this parameter.